Fairpointe Capital’s NeoGenomics NEO Stock Holding History

Fairpointe Capital’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	$2.17M	Hold	45,000	–	–	3.27%	6
2020 Q4	$2.42M	Hold	45,000	–	–	0.45%	45
2020 Q3	$1.66M	Sell	45,000 -15,000	-25%	-$558K	0.27%	47
2020 Q2	$1.86M	Sell	60,000 -90,000	-60%	-$2.49M	0.27%	49
2020 Q1	$4.14M	Hold	150,000	–	–	0.62%	44
2019 Q4	$4.39M	Sell	150,000 -23,277	-13%	-$554K	0.34%	44
2019 Q3	$3.31M	Sell	173,277 -30,000	-15%	-$704K	0.17%	48
2019 Q2	$4.46M	Sell	203,277 -7,530	-4%	-$165K	0.18%	48
2019 Q1	$4.31M	Hold	210,807	–	–	0.14%	46
2018 Q4	$2.66M	Sell	210,807 -67,325	-24%	-$1M	0.09%	52
2018 Q3	$4.27M	Hold	278,132	–	–	0.11%	50
2018 Q2	$3.65M	Hold	278,132	–	–	0.08%	46
2018 Q1	$2.27M	Hold	278,132	–	–	0.05%	51
2017 Q4	$2.46M	Buy	+278,132	New	+$2.56M	0.05%	52

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

KFO

Kopp Family Office Bloomington, Minnesota $163M AUM 22.57% 1-Year Est. Return

Fairpointe Capital's NEO Position: Q1 2021 in Review

Fairpointe Capital held its NeoGenomics (NEO) position steady in Q1 2021 at 45,000 shares worth $2.17M. The position accounts for 3.27% of the portfolio, ranked #6.

Fairpointe Capital first reported a position in NEO in Q4 2017 and has held it in 14 quarters since. The position peaked at $4.46M in Q2 2019. 332 funds tracked by Wall St. Rank hold NEO as of Q1 2021.

Fairpointe Capital held 45,000 shares of NeoGenomics worth $2.17M as of Q1 2021.
Fairpointe Capital left its NeoGenomics share count unchanged in Q1 2021.
NeoGenomics made up 3.27% of Fairpointe Capital's portfolio in Q1 2021, its #6 holding.
Fairpointe Capital first reported a position in NeoGenomics in Q4 2017 and has held it in 14 quarters since.
Fairpointe Capital's NeoGenomics position peaked at $4.46M in Q2 2019.
332 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.